Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
6.97
-0.34 (-4.65%)
At close: Oct 30, 2026, 4:00 PM EDT
6.95
-0.02 (-0.29%)
After-hours: Oct 30, 2026, 7:52 PM EDT
Ocular Therapeutix Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Ocular Therapeutix stock has a consensus rating of "Strong Buy" and an average price target of $25.45. The average 1-year stock price forecast is 265.14% higher than the current stock price, while the lowest is $14 (+100.86%) and the highest is $34 (+387.80%).
Price Target: $25.45 (+265.14%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ocular Therapeutix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +258.68% | Oct 20, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $27 | Buy | Maintains | $27 | +287.37% | Oct 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $31 | Buy | Maintains | $31 | +344.76% | Oct 12, 2026 |
| UBS | UBS | Buy Initiates $14 | Buy | Initiates | $14 | +100.86% | Oct 11, 2026 |
| Needham | Needham | Buy Maintains $18 | Buy | Maintains | $18 | +158.25% | Sep 28, 2026 |
Financial Forecast
Revenue This Year
52.84M
from 51.95M
Increased by 1.70%
Revenue Next Year
102.04M
from 52.84M
Increased by 93.13%
EPS This Year
-1.44
from -1.42
EPS Next Year
-1.48
from -1.44
EPS and Forward PE are based on non-GAAP adjusted numbers.